The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...

Myocardial infarction is an ischemic disease in which a coronary artery supplying blood to the heart muscle is stenotic or obstructed, resulting in cardiac tissue necrosis. Due to the irreversible ...

While there are therapies to aid in overall heart health, there are very few preventative therapies for heart failure after a significant heart attack, a serious condition that has a very significant ...

Credit: Getty Images. A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. The role of beta-blockers after acute ...

The world's first clinical trial to test glenzocimab as a potential new drug to improve the long-term outcomes for heart attack patients will take place in the UK. Glenzocimab is a humanised ...

Cardiovascular disease is by far the most common cause of death worldwide, and myocardial infarction is the most common acute event. For those who survive a myocardial infarction, the risk of a new ...

Cardiologist evaluation for post-noncardiac surgery PMI patients reduces one-year risks of major adverse cardiac events and all-cause death.

ST-segment myocardial infarction (STEMI) causes significant morbidity and mortality, with infarct size being the primary predictor of clinical outcome. Given imaging evidence that early IV metoprolol ...

Myocardial infarction, or a heart attack, remains the most common cause of heart failure (HF) worldwide. Although there are treatments that aid in overall heart health, there are few preventative ...

When the heart develops, some of its coronary blood vessels develop from cells lining the inner surface of the heart's ventricular chambers (endocardium). Novel findings suggest that new blood vessel ...